In clinical studies over the past 20 years, our licensed Immunitor oral pill immunotherapeutics have consistently proven the science and demonstrated superior safety and efficacy in diseases such as late-stage cancers, tuberculosis, HIV/AIDS, hepatitis.In many cases where other treatments have failed.
Key Capital is now working with Immunitor towards product registrations and commercializations that will contribute to a better healthcare future.
NEW YORK, NY, January 28, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that as SARS-CoV-2 continues to spread, and reports of increases in daily infections, hospitalizations, and deaths are becoming regular, Key Capital plans to market its Immunitor partnered potentially therapeutic oral pill as a supplement commencing early February.
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine
New York-based Key Capital Corporation announced independent laboratory testing of its partnered Immunitor COVID-19 patented oral pill vaccine in an ongoing university study is providing promising early support for the safety and efficacy of the vaccine.